Atea Pharmaceuticals (AVIR) said Wednesday that the first patient has been dosed in its late-stage trial comparing the combination regimen of bemnifosbuvir and ruzasvir with the combination regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus.
The bemnifosbuvir and ruzasvir regimen will be administered orally once a day for eight weeks in patients without cirrhosis or 12 weeks in patients with compensated cirrhosis, while the sofosbuvir and velpatasvir regimen will be administered orally once a day for 12 weeks, the company said.
The company said infection with chronic hepatitis C virus is the leading cause of liver cancer in the US, Europe and Japan.
Shares of Atea Pharmaceuticals were down more than 30% in recent premarket activity Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。